eligibility_summary
Inclusion: consent, ≥18, ECOG 0–1, resectable colorectal adenocarcinoma (CT cT3–4 N0–2 M0). Rectal: ≤T3a, N0, ≥5 cm from anal verge, no MRF invasion. Archival FFPE, cohort-matching molecular profile, no prior systemic/RT, adequate marrow/renal/hepatic, contraception/compliance. Exclusion: metastases, obstruction risk, need rectal RT, hypersensitivity, significant CV disease, HIV/active HBV/HCV, serious comorbidity, pregnancy, plus cohort-specific drug/genomic limits.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II window-of-opportunity umbrella trial in resectable colorectal cancer with short-course, molecularly matched neoadjuvant therapy before surgery. Drugs/types and mechanisms: - Trastuzumab deruxtecan (ADC): anti-HER2 antibody delivering topoisomerase I inhibitor, targets HER2-amplified cells. - Durvalumab (mAb): anti–PD-L1, blocks PD-1/PD-L1 signaling. - Panitumumab (mAb): anti-EGFR, inhibits EGFR signaling. - Botensilimab (mAb): anti–CTLA-4, enhances T-cell priming/activation. - Balstilimab (mAb): anti–PD-1, restores T-cell function. - Sotorasib (small molecule): covalent KRAS G12C inhibitor, suppresses RAS/MAPK. - Vorbipiprant (small molecule): EP4 antagonist, blocks PGE2–EP4 immunosuppression. - Nivolumab (mAb): anti–PD-1. Target cells/pathways: HER2/ERBB2+ tumor cells, EGFR-driven RAS/BRAF WT MSS tumors, KRAS G12C–mutant CRC (with EGFR feedback blockade), PD-1/PD-L1 and CTLA-4 checkpoints on T cells, ultramutated POLE/POLD1 tumors (ICB-sensitive), EP4-mediated myeloid/T-cell suppression in MSS.